Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 0.69 |
| ▸ | LYPLA1 | O75608 | 4/20 | 0.64 |
| ▸ | LYPLA2 | O95372 | 4/20 | 0.64 |
| ▸ | PRKCA | P17252 | 3/20 | 0.59 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.56 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.55 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | PRKCB | P05771 | 1/20 | 0.55 |
| ▸ | PRKCH | P24723 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 6/20 | 0.50 |
| ▸ | PNLIP | P16233 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19514928 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL16617217 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL15536871 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL21679666 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL21679653 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL21679665 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL19576215 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL16617219 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL21679663 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A | |
| SCHEMBL21679661 | 1.00 | DAGLA (0.69) | DAGLALYPLA1LYPLA2PRKCAABHD16A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313669-A1 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | THE SCRIPPS RESEARCH INSTITUTE | 2017-11-02 | — | — | US | disclosed |
| US-20170313669-A1 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | THE SCRIPPS RESEARCH INSTITUTE | 2017-11-02 | — | — | US | disclosed |
| WO-2016069542-A2 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-05-06 | — | — | WO | disclosed |
| EP-1861113-B1 | USE OF AN ONION EXTRACT FOR MAKING A COMPOSITION TO CONTROL WEIGHT GAIN | NATUREX (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1680106-B1 | COMBINATION TREATMENT OF OBESITY INVOLVING 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY AND LIPASE INHIBITORS | SOLVAY PHARM GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| CN-101189248-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-101180097-A | Novel phosphinic acid-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-1997364-A | Display CB1New medical use of compounds with antagonistic activity and combination therapy comprising said compounds | SOLVAY PHARM GMBH (DE) | 2007-07-11 | — | — | CN | disclosed |
| CN-1921849-A | Comprises having a CB1Combination therapy for obesity with antagonistically active 4, 5-dihydro-1H-pyrazole derivatives | SOLVAY PHARM GMBH (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1753413-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB SB 1/SB -ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| CN-1867332-A | Comprising a selective CB1Combination therapy of obesity with antagonists and lipase inhibitors | SOLVAY PHARM GMBH (DE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1680116-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1680106-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY AND LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050143441-A1 | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039550-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039579-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039566-A1 | COMBINATION TREATMENT OF OBESITY INVOLVING 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY AND LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143441-A1 | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | PNLIP, LPCAT3, CNR2 | DAGLA 21/4885LYPLA1 26/4885LYPLA2 17/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | DAGLA 75/4885LYPLA1 23/4885LYPLA2 18/4885 |
| US-20170313669-A1 | LACTONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD16A, ABHD12, ABHD11 | DAGLA 381/4885LYPLA1 41/4885LYPLA2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.